Fig. 5

Patients’ recommendation of THC:CBD overall and in relation to severity of spasticity. The likelihood of recommendation of THC:CBD in the overall patient group and in relation to the severity of spasticity (a) was assessed using the Net Promoter Score (NPS): unlikely recommendation (0 to 6 points); indifferent recommendation (7 to 8 points); likely recommendation (9 to 10 points). The patients’ perception of spasticity was assessed using the Numeric Rating Scale (NRS): Patients with moderate to severe spasticity (NRS ≥ 4), patients with mild or no spasticity (NRS < 4). The total NPS (b) is calculated by subtracting the percentage of patients who are detractors from the percentage of patients who are promoters. Patients who respond with a score of 9 to 10 are considered as “promoters”. Those who rate the medication with 7 or 8 are classified as “indifferent” (not shown in b). The group of patients who express an unlikely recommendation (6 to 0 points) are defined as “detractors”. n = number of patients